(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 97.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Abeona Therapeutics's revenue in 2026 is $25,520,000.On average, 9 Wall Street analysts forecast ABEO's revenue for 2026 to be $3,402,906,484, with the lowest ABEO revenue forecast at $2,605,875,655, and the highest ABEO revenue forecast at $4,741,012,481. On average, 9 Wall Street analysts forecast ABEO's revenue for 2027 to be $8,595,901,435, with the lowest ABEO revenue forecast at $5,301,415,848, and the highest ABEO revenue forecast at $11,009,066,953.
In 2028, ABEO is forecast to generate $10,482,973,996 in revenue, with the lowest revenue forecast at $7,793,609,677 and the highest revenue forecast at $12,917,297,600.